Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Povetacicept - Vertex Pharmaceuticals

Next Previous
Drug Profile

Povetacicept - Vertex Pharmaceuticals

Alternative Names: ALPN 30x; ALPN-303

Latest Information Update: 22 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alpine Immune Sciences
  • Developer Alpine Immune Sciences; Vertex Pharmaceuticals
  • Class Anti-inflammatories; Immunoglobulin fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Urologics
  • Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III IgA nephropathy
  • Phase I/II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Autoimmune disorders; Glomerulonephritis
  • Phase I Lupus nephritis; Membranous glomerulonephritis; Systemic lupus erythematosus
  • Preclinical Myasthenia gravis
  • No development reported Sjogren's syndrome

Most Recent Events

  • 07 Aug 2025 ZAI Labs and Vertex Pharmaceuticals plans a phase II/III trial for Membranous glomerulonephritis in China in second half of 2025
  • 23 Jun 2025 Povetacicept licensed to Ono Pharmaceutical in Japan and South Korea
  • 23 Jun 2025 Japan PMDA and South Korean MFDS approves CTA for the phase III RAINIER trial of Povetacicept in IgA nephropathy before June 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top